Literature DB >> 33638714

Prolonged onset and duration of action of rocuronium after accidental subcutaneous injection in a patient with chronic renal failure-a case report.

Akira Doshu-Kajiura1, Junko Suzuki2, Takahiro Suzuki2.   

Abstract

BACKGROUND: Drugs administered subcutaneously have delayed onset and prolonged duration of action versus those given intravenously. Since the duration of action of rocuronium is prolonged in patients with renal dysfunction, subcutaneous administration of rocuronium to such patients might significantly prolong its effect. CASE
PRESENTATION: A 51-year-old female with chronic renal failure was accidentally administered 1.04 mg/kg rocuronium subcutaneously. Marked prolongation of onset and duration of action of rocuronium were detected on acceleromyography. Slow development of the neuromuscular block was still observed at 100 min after injection. Administration of 4.5 mg/kg sugammadex at 140 min after rocuronium injection facilitated recovery from a train-of-four (TOF) count of 2 to a TOF ratio of 100% within 5 min. No symptoms of postoperative recurarization and upper airway obstruction were observed.
CONCLUSION: Neuromuscular monitoring is necessary to evaluate the progress and depth of neuromuscular block, particularly when rocuronium is inadvertently administered subcutaneously.

Entities:  

Keywords:  Acceleromyograph; Hemodialysis; Pharmacodynamics; Rapid sequence induction; Rocuronium; Subcutaneous injection; Sugammadex

Year:  2021        PMID: 33638714      PMCID: PMC7914319          DOI: 10.1186/s40981-021-00421-3

Source DB:  PubMed          Journal:  JA Clin Rep        ISSN: 2363-9024


  7 in total

1.  The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis.

Authors:  M M van Miert; N B Eastwood; A H Boyd; C J Parker; J M Hunter
Journal:  Br J Clin Pharmacol       Date:  1997-08       Impact factor: 4.335

2.  Neuromuscular effects of subcutaneous administration of pancuronium.

Authors:  H Iwasaki; A Namiki; T Omote; K Omote
Journal:  Anesthesiology       Date:  1992-06       Impact factor: 7.892

3.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

4.  Sugammadex Reversal of a Large Subcutaneous Depot of Rocuronium in a Dialysis Patient: A Case Report.

Authors:  Sagar R Navare; Oscar Garcia Medina; Richard C Prielipp; Julia L Weinkauf
Journal:  A A Pract       Date:  2019-05-15

5.  Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.

Authors:  L M Staals; M M J Snoeck; J J Driessen; H W van Hamersvelt; E A Flockton; M W van den Heuvel; J M Hunter
Journal:  Br J Anaesth       Date:  2010-01       Impact factor: 9.166

6.  Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles.

Authors:  T Suzuki; H Mizutani; E Miyake; N Fukano; S Saeki; S Ogawa
Journal:  Acta Anaesthesiol Scand       Date:  2009-07-22       Impact factor: 2.105

7.  Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function.

Authors:  L M Staals; M M J Snoeck; J J Driessen; E A Flockton; M Heeringa; J M Hunter
Journal:  Br J Anaesth       Date:  2008-07-23       Impact factor: 9.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.